Benefits and risks of pharmacological treatments for essential tremor

Kelly E. Lyons, Rajesh Pahwa, Cynthia L. Comella, Mahmood Sayied Eisa, Rodger J. Elble, Stanley Fahn, Joseph Jankovic, Jorge L. Juncos, William C. Koller, William G. Ondo, Kapil Dev Sethi, Matthew B. Stern, Caroline M. Tanner, Ron Tintner, Ray L. Watts

Research output: Contribution to journalReview article

73 Citations (Scopus)

Abstract

Essential tremor can cause significant functional disability in some patients. The arms are the most common body part affected and cause the most functional disability. The treatment of essential tremor includes medications, surgical options and other forms of therapy. Presently there is no cure for essential tremor nor are there any medications that can slow the progression of tremor. Treatment for essential tremor is recommended if the tremor causes functional disability. If the tremor is disabling only during periods of stress and anxiety, propranolol and benzodiazepines can be used during those periods when the tremor causes functional disability. The currently available medications can improve tremor in approximately 50% of the patients. If the tremor is disabling, treatment should be initiated with either primidone or propranolol. If either primidone or propranolol do not provide adequate control of the tremor, then the medications can be used in combination. If patients experience adverse effects with propranolol, occasionally other β-adrenoceptor antagonists (such as atenolol or metoprolol) can be used. If primidone and propranolol do not provide adequate control of tremor, occasionally the use of benzodiazepines (such as clonazepam) can provide benefit. Other medications that may be helpful include gabapentin or topiramate. If a patient has disabling head or voice tremor, botulinum toxin injections into the muscles may provide relief from the tremor. Botulinum toxin in the hand muscles for hand tremor can result in bothersome hand weakness and is not widely used. There are other medications that have been tried in essential tremor and have questionable efficacy. These drugs include carbonic anhydrase inhibitors (e.g. methazolamide), phenobarbital, calcium channel antagonists (e.g. nimodipine), isoniazid, clonidine, clozapine and mirtazapine. If the patient still has disabling tremor after medication trials, surgical options are usually considered. Surgical options include thalamotomy and deep brain stimulation of the thalamus. These surgical options provide adequate tremor control in approximately 90% of the patients. Surgical morbidity and mortality for these procedures is low. Deep brain stimulation and thalamotomy have been shown to have comparable efficacy but fewer complications have been reported with deep brain stimulation. In patients undergoing bilateral procedures deep brain stimulation of the thalamus is the procedure of choice to avoid adverse effects seen with bilateral ablative procedures. The use of medication and/or surgery can provide adequate tremor control in the majority of the patients.

Original languageEnglish (US)
Pages (from-to)461-481
Number of pages21
JournalDrug Safety
Volume26
Issue number7
DOIs
StatePublished - Jun 9 2003

Fingerprint

Essential Tremor
Tremor
Propranolol
Primidone
Pharmacology
Brain
Botulinum Toxins
Benzodiazepines
Muscle
Deep Brain Stimulation
Methazolamide
Carbonic Anhydrase Inhibitors
Therapeutics
Clonazepam
Nimodipine
Metoprolol
Atenolol
Clozapine
Isoniazid
Calcium Channel Blockers

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Lyons, K. E., Pahwa, R., Comella, C. L., Eisa, M. S., Elble, R. J., Fahn, S., ... Watts, R. L. (2003). Benefits and risks of pharmacological treatments for essential tremor. Drug Safety, 26(7), 461-481. https://doi.org/10.2165/00002018-200326070-00003

Benefits and risks of pharmacological treatments for essential tremor. / Lyons, Kelly E.; Pahwa, Rajesh; Comella, Cynthia L.; Eisa, Mahmood Sayied; Elble, Rodger J.; Fahn, Stanley; Jankovic, Joseph; Juncos, Jorge L.; Koller, William C.; Ondo, William G.; Sethi, Kapil Dev; Stern, Matthew B.; Tanner, Caroline M.; Tintner, Ron; Watts, Ray L.

In: Drug Safety, Vol. 26, No. 7, 09.06.2003, p. 461-481.

Research output: Contribution to journalReview article

Lyons, KE, Pahwa, R, Comella, CL, Eisa, MS, Elble, RJ, Fahn, S, Jankovic, J, Juncos, JL, Koller, WC, Ondo, WG, Sethi, KD, Stern, MB, Tanner, CM, Tintner, R & Watts, RL 2003, 'Benefits and risks of pharmacological treatments for essential tremor', Drug Safety, vol. 26, no. 7, pp. 461-481. https://doi.org/10.2165/00002018-200326070-00003
Lyons, Kelly E. ; Pahwa, Rajesh ; Comella, Cynthia L. ; Eisa, Mahmood Sayied ; Elble, Rodger J. ; Fahn, Stanley ; Jankovic, Joseph ; Juncos, Jorge L. ; Koller, William C. ; Ondo, William G. ; Sethi, Kapil Dev ; Stern, Matthew B. ; Tanner, Caroline M. ; Tintner, Ron ; Watts, Ray L. / Benefits and risks of pharmacological treatments for essential tremor. In: Drug Safety. 2003 ; Vol. 26, No. 7. pp. 461-481.
@article{d996a16226ab4d4688cd5718294f7c11,
title = "Benefits and risks of pharmacological treatments for essential tremor",
abstract = "Essential tremor can cause significant functional disability in some patients. The arms are the most common body part affected and cause the most functional disability. The treatment of essential tremor includes medications, surgical options and other forms of therapy. Presently there is no cure for essential tremor nor are there any medications that can slow the progression of tremor. Treatment for essential tremor is recommended if the tremor causes functional disability. If the tremor is disabling only during periods of stress and anxiety, propranolol and benzodiazepines can be used during those periods when the tremor causes functional disability. The currently available medications can improve tremor in approximately 50{\%} of the patients. If the tremor is disabling, treatment should be initiated with either primidone or propranolol. If either primidone or propranolol do not provide adequate control of the tremor, then the medications can be used in combination. If patients experience adverse effects with propranolol, occasionally other β-adrenoceptor antagonists (such as atenolol or metoprolol) can be used. If primidone and propranolol do not provide adequate control of tremor, occasionally the use of benzodiazepines (such as clonazepam) can provide benefit. Other medications that may be helpful include gabapentin or topiramate. If a patient has disabling head or voice tremor, botulinum toxin injections into the muscles may provide relief from the tremor. Botulinum toxin in the hand muscles for hand tremor can result in bothersome hand weakness and is not widely used. There are other medications that have been tried in essential tremor and have questionable efficacy. These drugs include carbonic anhydrase inhibitors (e.g. methazolamide), phenobarbital, calcium channel antagonists (e.g. nimodipine), isoniazid, clonidine, clozapine and mirtazapine. If the patient still has disabling tremor after medication trials, surgical options are usually considered. Surgical options include thalamotomy and deep brain stimulation of the thalamus. These surgical options provide adequate tremor control in approximately 90{\%} of the patients. Surgical morbidity and mortality for these procedures is low. Deep brain stimulation and thalamotomy have been shown to have comparable efficacy but fewer complications have been reported with deep brain stimulation. In patients undergoing bilateral procedures deep brain stimulation of the thalamus is the procedure of choice to avoid adverse effects seen with bilateral ablative procedures. The use of medication and/or surgery can provide adequate tremor control in the majority of the patients.",
author = "Lyons, {Kelly E.} and Rajesh Pahwa and Comella, {Cynthia L.} and Eisa, {Mahmood Sayied} and Elble, {Rodger J.} and Stanley Fahn and Joseph Jankovic and Juncos, {Jorge L.} and Koller, {William C.} and Ondo, {William G.} and Sethi, {Kapil Dev} and Stern, {Matthew B.} and Tanner, {Caroline M.} and Ron Tintner and Watts, {Ray L.}",
year = "2003",
month = "6",
day = "9",
doi = "10.2165/00002018-200326070-00003",
language = "English (US)",
volume = "26",
pages = "461--481",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "7",

}

TY - JOUR

T1 - Benefits and risks of pharmacological treatments for essential tremor

AU - Lyons, Kelly E.

AU - Pahwa, Rajesh

AU - Comella, Cynthia L.

AU - Eisa, Mahmood Sayied

AU - Elble, Rodger J.

AU - Fahn, Stanley

AU - Jankovic, Joseph

AU - Juncos, Jorge L.

AU - Koller, William C.

AU - Ondo, William G.

AU - Sethi, Kapil Dev

AU - Stern, Matthew B.

AU - Tanner, Caroline M.

AU - Tintner, Ron

AU - Watts, Ray L.

PY - 2003/6/9

Y1 - 2003/6/9

N2 - Essential tremor can cause significant functional disability in some patients. The arms are the most common body part affected and cause the most functional disability. The treatment of essential tremor includes medications, surgical options and other forms of therapy. Presently there is no cure for essential tremor nor are there any medications that can slow the progression of tremor. Treatment for essential tremor is recommended if the tremor causes functional disability. If the tremor is disabling only during periods of stress and anxiety, propranolol and benzodiazepines can be used during those periods when the tremor causes functional disability. The currently available medications can improve tremor in approximately 50% of the patients. If the tremor is disabling, treatment should be initiated with either primidone or propranolol. If either primidone or propranolol do not provide adequate control of the tremor, then the medications can be used in combination. If patients experience adverse effects with propranolol, occasionally other β-adrenoceptor antagonists (such as atenolol or metoprolol) can be used. If primidone and propranolol do not provide adequate control of tremor, occasionally the use of benzodiazepines (such as clonazepam) can provide benefit. Other medications that may be helpful include gabapentin or topiramate. If a patient has disabling head or voice tremor, botulinum toxin injections into the muscles may provide relief from the tremor. Botulinum toxin in the hand muscles for hand tremor can result in bothersome hand weakness and is not widely used. There are other medications that have been tried in essential tremor and have questionable efficacy. These drugs include carbonic anhydrase inhibitors (e.g. methazolamide), phenobarbital, calcium channel antagonists (e.g. nimodipine), isoniazid, clonidine, clozapine and mirtazapine. If the patient still has disabling tremor after medication trials, surgical options are usually considered. Surgical options include thalamotomy and deep brain stimulation of the thalamus. These surgical options provide adequate tremor control in approximately 90% of the patients. Surgical morbidity and mortality for these procedures is low. Deep brain stimulation and thalamotomy have been shown to have comparable efficacy but fewer complications have been reported with deep brain stimulation. In patients undergoing bilateral procedures deep brain stimulation of the thalamus is the procedure of choice to avoid adverse effects seen with bilateral ablative procedures. The use of medication and/or surgery can provide adequate tremor control in the majority of the patients.

AB - Essential tremor can cause significant functional disability in some patients. The arms are the most common body part affected and cause the most functional disability. The treatment of essential tremor includes medications, surgical options and other forms of therapy. Presently there is no cure for essential tremor nor are there any medications that can slow the progression of tremor. Treatment for essential tremor is recommended if the tremor causes functional disability. If the tremor is disabling only during periods of stress and anxiety, propranolol and benzodiazepines can be used during those periods when the tremor causes functional disability. The currently available medications can improve tremor in approximately 50% of the patients. If the tremor is disabling, treatment should be initiated with either primidone or propranolol. If either primidone or propranolol do not provide adequate control of the tremor, then the medications can be used in combination. If patients experience adverse effects with propranolol, occasionally other β-adrenoceptor antagonists (such as atenolol or metoprolol) can be used. If primidone and propranolol do not provide adequate control of tremor, occasionally the use of benzodiazepines (such as clonazepam) can provide benefit. Other medications that may be helpful include gabapentin or topiramate. If a patient has disabling head or voice tremor, botulinum toxin injections into the muscles may provide relief from the tremor. Botulinum toxin in the hand muscles for hand tremor can result in bothersome hand weakness and is not widely used. There are other medications that have been tried in essential tremor and have questionable efficacy. These drugs include carbonic anhydrase inhibitors (e.g. methazolamide), phenobarbital, calcium channel antagonists (e.g. nimodipine), isoniazid, clonidine, clozapine and mirtazapine. If the patient still has disabling tremor after medication trials, surgical options are usually considered. Surgical options include thalamotomy and deep brain stimulation of the thalamus. These surgical options provide adequate tremor control in approximately 90% of the patients. Surgical morbidity and mortality for these procedures is low. Deep brain stimulation and thalamotomy have been shown to have comparable efficacy but fewer complications have been reported with deep brain stimulation. In patients undergoing bilateral procedures deep brain stimulation of the thalamus is the procedure of choice to avoid adverse effects seen with bilateral ablative procedures. The use of medication and/or surgery can provide adequate tremor control in the majority of the patients.

UR - http://www.scopus.com/inward/record.url?scp=0037902473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037902473&partnerID=8YFLogxK

U2 - 10.2165/00002018-200326070-00003

DO - 10.2165/00002018-200326070-00003

M3 - Review article

VL - 26

SP - 461

EP - 481

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 7

ER -